Sergio Cifuentes Canaval: My takeaways from new analysis of the CheckMate 9ER trial
Sergio Cifuentes Canaval, Cancer Research Project Manager at
“Nivolumab + Cabozantinib: Numbers Confirm Efficacy in Advanced Kidney Cancer: CM 9ER
New analysis of the CheckMate 9ER trial, here are my takeaways:
Survival:
Nivolumab + Cabozantinib significantly improved both PFS and OS compared to Sunitinib.
– PFS: 16.6 m vs 8.4 m (HR 0.59; 95% CI 0.49-0.71)
– OS: 49.5 m vs 35.5 m (HR 0.70; 95% CI 0.56-0.87)
Response Rates:
Patients receiving Nivolumab + Cabozantinib reached a
– CR: 13% vs 5%
– ORR: 56% (50-62%) vs 28% (23-33%)
– mDoR: 22.1 m vs 16.1 m
Benefit Across Risk Groups:
The combination therapy showed benefits for patients in intermediate, poor, and intermediate/poor risk groups based on the IMDC score.
Higher Impact for High-Risk Patients (IMDC score high).
Significant Mexican Participation: We’re proud to note that a significant portion of the study population (35%) were from Mexico!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023